Medical science liaison

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Retrieved on: 
Thursday, March 28, 2024
Narcolepsy, Exercise, Somnolence, New Drug Application, Patient, Visual analogue scale, Sale, NDA, G&A, Arimoclomol, Nature, IND, Bank statement, Microsoft Access, Investment, Therapy, Priority review, Corporation, Audit committee, Research, Niemann–Pick disease, Medical science liaison, Sleep disorder, Brain, Trial of the century, Safety, Interim, Food, Sleep, QuickStart, Disease, FY, Acquisition, Emetine, UCD, COL3A1, Celiprolol, Syndrome, FDA, Marketing, Conference call, Conference, EAP, SDX, NPC, Epworth Sleepiness Scale, Idiopathic hypersomnia, Physician, PDUFA, Pharmaceutical industry

CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023. 

Key Points: 
  • ET
    CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023.
  • “We made solid progress on our key priorities in 2023,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • Overview of Q4 2023 and FY 2023 Financial Results:
    Net revenue for Q4 2023 was $13.2 million, compared to prior year Q4 net revenue of $2.2 million.
  • ET, to discuss its corporate and financial results for Q4 and FY 2023.

Alucio™ Unveils New Meeting Features in Beacon to Elevate HCP Engagement

Retrieved on: 
Wednesday, February 28, 2024
SAN, HCP, Chart, Google Meet, Health, Product management, Medical science liaison, Health care, Protagonist, Therapy, Market access, Microsoft, Zoom

SAN FRANCISCO, Feb. 28, 2024 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced important enhancements to the presentation mode within Beacon. Beacon is a modern content activation and Healthcare Professional (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.

Key Points: 
  • Beacon is a modern content activation and Healthcare Professional (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.
  • Users are reacting very positively to these enhancements and the other engagement features in Beacon.
  • "We are very excited to release these new features to further enhance the effectiveness of meetings conducted from Beacon," says Lauren Keyes, Alucio Director of Product Management.
  • "We continue to focus on making the meeting experience on Beacon as easy and impactful as possible."

Alucio™ Makes Major Strides, Finishing Record Year in 2023

Retrieved on: 
Tuesday, January 16, 2024
Artificial intelligence, Research, SAN, ARR, HCP, CLM, Market access, KOL, Machine learning, Medical science liaison

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Alucio ™, a fast-growing provider of cloud-based software for the life sciences industry, delivered noteworthy results in 2023, and continued to deepen and extend Beacon's scientific exchange capabilities for users. Beacon, the company's flagship product, is a modern content activation and HCP engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.

Key Points: 
  • "We are very proud of what we were able to achieve as an organization in 2023.
  • In fact, Alucio achieved 100% customer retention in 2023 with all clients remaining active and referenceable.
  • "We are very proud of what we were able to achieve as an organization in 2023.
  • "We'll continue to innovate and work to delight our customers in 2024 to further sustain our success."

Alucio™ Unveils Beacon Hub 2.0 to Further Elevate HCP and Stakeholder Engagement

Retrieved on: 
Monday, December 4, 2023
HCP, Hub, Research, SAN, Congress, Medical Affairs Bureau, Health, Social media, Health care, Market access, Medical science liaison, Surveying, Beacon

SAN FRANCISCO, Dec. 4, 2023 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced a major upgrade of its Beacon Hub feature which offers unique, ongoing engagement capabilities within Alucio's flagship product, Beacon. Beacon is a modern content activation and Healthcare Professional (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.

Key Points: 
  • Beacon is a modern content activation and Healthcare Professional (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.
  • Beacon Hub is a very unique and flexible solution that allows MSLs and Medical Affairs teams to respond to stakeholder needs," said Nika Sajed, Principal Medical Scientist at Gilead.
  • This latest release of Beacon Hub integrates additional, distinctive features that provide added benefits to HCPs, Medical Affairs teams and other important stakeholders.
  • Beacon Hub is a very unique and flexible solution that allows MSLs and Medical Affairs teams to respond to stakeholder needs, increase connectivity and deepen relationships."

PharmaForce International: Leading Oncology Companies in Europe Make Key Changes to Commercial Affairs Personnel in 2023

Retrieved on: 
Wednesday, November 29, 2023
PFI, Microsoft PowerPoint, Multimedia, Sales, Intelligence, Marketing, Benchmarking, Growth, Market access, Medical science liaison, Nursing, Retail, Medicine, Oncology

Of the companies profiled in these reports, there were many noteworthy organizational changes that occurred in 2023.

Key Points: 
  • Of the companies profiled in these reports, there were many noteworthy organizational changes that occurred in 2023.
  • Since the prior Oncology study from 2022, there were overall increases in the total number of Oncology Medical personnel captured in these reports.
  • While the Medical and Market access personnel experienced growth in the EU Oncology market, the Sales personnel did not.
  • Each country saw either decreases or no major changes in the total number of Oncology Sales personnel.

Alucio™ Adds Sage Therapeutics to Further Deepen Its Customer Base

Retrieved on: 
Monday, November 6, 2023
Medical Affairs Bureau, Internet, Library and Information Science Abstracts, Medical science liaison, MSL, Entrepreneurship, Customer success, Expert Field Medical Badge, HCP, Tablet, Opinion, KOL, Market access, Patient, CMS, SAN, Health care, Management, Beacon, Sage

SAN FRANCISCO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced that Sage Therapeutics (Sage) has chosen Alucio's Beacon platform for use by their Medical Affairs and Field Medical teams. Beacon is a modern content activation and healthcare professionals (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.

Key Points: 
  • "We are thrilled that Sage selected Beacon as part of their vision plan", said Jeff Asada, Co-Founder & Head of Customer Success at Alucio, "We look forward to supporting their growing commercialization success while ensuring that Sage's field medical team can deepen KOL relationships."
  • Through this agreement, Alucio will support Sage in fulfilling its scientific exchange objectives as they deliver new approaches for patients suffering from brain health disorders.
  • Sage will leverage Beacon's powerful content library management and on-demand publishing functionality to organize and distribute documents to their MSL team.
  • Sage adds to Alucio's fast-growing roster of life science companies that have become Beacon customers.

Alucio™ and The Medical Science Liaison Society Publish Latest Content Customization Trends for KOL Engagement

Retrieved on: 
Tuesday, October 3, 2023
Microsoft PowerPoint, KOL, Medical Affairs Bureau, Health care, Market access, MSL, Library and Information Science Abstracts, HCP, Organization, Health, Animation, SAN, Medical science liaison, MSLS, HTML5, PDF, Management, Beacon

 SAN FRANCISCO, Oct. 3, 2023 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, recently published new scientific exchange trends in collaboration with The Medical Science Liaison Society (MSLS). The Medical Science Liaison Society is the only 501c3 non-profit organization exclusively dedicated to advancing the global MSL profession.

Key Points: 
  • The Medical Science Liaison Society is the only 501c3 non-profit organization exclusively dedicated to advancing the global MSL profession.
  • The reliance on more traditional, static content can lead to undifferentiated and less-impactful scientific storytelling that falls short of today's KOL expectations.
  • Beacon is a modern content distribution, activation, and Healthcare Professional (HCP) engagement platform built specifically for MSLs, Medical Affairs professionals, and Market Access teams.
  • It enables MSLs to convey the latest medical advancements with clarity, fostering informed decision-making and ultimately improving patient care.

AVITA Medical Reports Second Quarter Financial Results

Retrieved on: 
Thursday, August 10, 2023
Biomedical Advanced Research and Development Authority, Avita Medical, AVH, Anticipation, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Human services, Telephone, Office of Inspector General, U.S. Department of Health and Human Services, ASX, Research, Medical science liaison, Assistant, Regenerative medicine, Development, PMA, Patient, Growth, Vitiligo, FDA, BARDA, Medical device, Video game, Pharmaceutical industry

VALENCIA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the second quarter June 30, 2023.

Key Points: 
  • VALENCIA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the second quarter June 30, 2023.
  • “As anticipated, our expanded U.S. commercial organization was fully prepared for the FDA approval of full-thickness skin defects.
  • Gross profit margin decreased by 2% to 81% compared to 83% for the second quarter of 2022.
  • The Company will host a conference call to discuss the second quarter financial results and, recent business highlights on Thursday, August 10, 2023, at 1:30 p.m. Pacific Time.

Alucio™ Enhances Hybrid Engagement Flexibility by Deepening PowerPoint Integration

Retrieved on: 
Tuesday, August 1, 2023
Product management, Microsoft PowerPoint, Medical Affairs Bureau, Health care, Market access, Library and Information Science Abstracts, Therapure BioPharma Inc, HCP, Health, SAN, PPT, CRM, Medical science liaison, Mobile phone, Surveying, Beacon

SAN FRANCISCO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced a new enhancement that enables connectivity to the Beacon scientific exchange platform from inside of PowerPoint. This option allows Beacon users to access powerful features of the platform directly from designated PPT files. Beacon is a modern content activation and Healthcare Professional (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.

Key Points: 
  • Beacon is a modern content activation and Healthcare Professional (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.
  • This enhanced connectivity between Beacon and PowerPoint ensures that files processed through the platform can immediately access key features from within the PowerPoint application.
  • This continuous and seamless integration provides field teams with additional meeting options in today's hybrid engagement environment.
  • This new integration capability provides users with additional flexibility and convenience in accessing key Beacon features from within that application," explained Lauren Keyes, Director of Product Management.

Quarterly Activities Update: Encouraging Growth for geneType Commercial Test Volume

Retrieved on: 
Friday, July 28, 2023
Pancreatic cancer, BIO, UK Biobank, Medical Affairs Bureau, Partnership, Prostate cancer, GTG, Single-nucleotide polymorphism, PRS, NATA, Cancer, Risk assessment, MSL, Prostate, Medical science liaison, Publication, ASCO, Genetypes, CLIA, Traction, Patient, Risk, 40th National Television Festival, Growth, Diagnosis, Mortality, R, Health, Society, Disease, Tourism, Pharmaceutical industry, Dairy, Vaccine, Medical imaging, Melanoma

GeneType Multi-risk test gaining traction with 250% growth in commercial samples received compared with the prior quarter off a low initial base.

Key Points: 
  • GeneType Multi-risk test gaining traction with 250% growth in commercial samples received compared with the prior quarter off a low initial base.
  • 20 Medical practices in the U.S. and Australia now repeatedly referring samples for geneType testing – adding new practices incrementally every week.
  • Growth in the commercial traction of the company’s geneType brand was experienced in both Australia and the U.S.
  • Implementing geneType risk assessment test for pancreatic cancer will help doctors diagnose the disease and intervene earlier, reducing this appalling mortality.